Hervé Brailly, CEO, is invited to the panel discussion "French Public Markets – Breakthrough Technologies Panel".
Zurich,Switzerland
More info
New data presented at the Annual Meeting of the American Society of Hematology (“ASH”)
December 7, 2009
- Updated Phase II interim results with IPH 1101 in non-Hodgkin’s lymphoma on a larger cohort confirming encouraging trend in complete response rate
- Update on IPH 2101 Phase I trials and new set of pre-clinical data
- Innate Pharma’s lead drug-candidates presented during two oral and five posters sessions, reinforcing the Company’s presence in the hemato-oncology scientific and medical communities
| Download Area |
|---|
| PR in english |
| CP en français |